BC Extra | Aug 7, 2018
Company News

Management tracks: GSK, J&J, Denali

GlaxoSmithKline plc (NYSE:GSK; LSE:GSK) hired Iain Mackay as CFO and executive director. Mackay, who is group finance director at HSBC, will join GSK on Jan. 14, 2019 as CFO designate and take formal accountability as...
BC Extra | Aug 2, 2018
Company News

Management tracks: Omeros, EdiGene

Omeros Corp. (NASDAQ:OMER) hired Eckhard Leifke as CMO and VP of clinical development. He was global project head/VP of early project and external opportunities - cardiovascular and metabolism and global head/VP of late-stage development diabetes at...
BC Extra | Jun 15, 2018
Company News

Management tracks: JHL, Aclaris, CytomX

Biosimilars company JHL Biotech Inc. (Zhubei, Taiwan) hired Ellis Chu as CFO. He was managing director and head of greater China at Ion Pacific Ltd., an Asia-focused venture capital merchant bank. Dermatology company Aclaris Therapeutics...
BC Week In Review | Dec 8, 2017
Clinical News

Neuralstem reports additional Phase II data for NSI-189 in MDD

Neuralstem Inc. (NASDAQ:CUR) reported additional data from a Phase II trial of NSI-189 to treat major depressive disorder (MDD). In July, the company reported top-line data showing that both doses of NSI-189 missed the trial's...
BC Extra | Dec 6, 2017
Clinical News

Neuralstem rebounds on additional MDD data

Neuralstem Inc. (NASDAQ:CUR) gained $1.97 (176%) to $3.09 on Tuesday after reporting additional data from a Phase II trial of NSI-189 to treat major depressive disorder. In July, the company's stock fell 50% to $2.81...
BC Extra | Nov 9, 2017
Company News

Management tracks: Pfizer, Hansa

Pfizer Inc. (NYSE:PFE) hired Amrit Ray as global president of Pfizer essential health, R&D, effective Friday. He was SVP of external affairs at Johnson & Johnson (NYSE:JNJ). In his new role, Ray will be responsible...
BioCentury | Oct 6, 2017
Finance

High as a Kite

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...
BC Week In Review | Jul 28, 2017
Clinical News

Neuralstem's NSI-189 misses in Phase II for MDD

Neuralstem Inc. (NASDAQ:CUR) reported top-line data from a Phase II trial in 220 patients with major depressive disorder (MDD) showing that once- and twice-daily 40 mg doses of NSI-189 each missed the primary endpoint of...
BC Extra | Jul 25, 2017
Clinical News

Neuralstem sags after Phase II miss in MDD

Neuralstem Inc. (NASDAQ:CUR) fell $2.77 (50%) to $2.81 on Tuesday after it said lead compound NSI-189 missed the primary endpoint in a Phase II trial to treat major depressive disorder. Compared to placebo, NSI-189 failed...
BC Week In Review | Apr 13, 2017
Clinical News

Human neural stem cells: Ph I amended

Neuralstem amended an open-label, U.S. Phase I trial evaluating injectable NSI-566 to enroll an additional cohort of 4 patients with American Spinal Injury Association Impairment Scale level A (AIS-A) complete, quadriplegic, cervical injuries involving C5-C7...
Items per page:
1 - 10 of 123
BC Extra | Aug 7, 2018
Company News

Management tracks: GSK, J&J, Denali

GlaxoSmithKline plc (NYSE:GSK; LSE:GSK) hired Iain Mackay as CFO and executive director. Mackay, who is group finance director at HSBC, will join GSK on Jan. 14, 2019 as CFO designate and take formal accountability as...
BC Extra | Aug 2, 2018
Company News

Management tracks: Omeros, EdiGene

Omeros Corp. (NASDAQ:OMER) hired Eckhard Leifke as CMO and VP of clinical development. He was global project head/VP of early project and external opportunities - cardiovascular and metabolism and global head/VP of late-stage development diabetes at...
BC Extra | Jun 15, 2018
Company News

Management tracks: JHL, Aclaris, CytomX

Biosimilars company JHL Biotech Inc. (Zhubei, Taiwan) hired Ellis Chu as CFO. He was managing director and head of greater China at Ion Pacific Ltd., an Asia-focused venture capital merchant bank. Dermatology company Aclaris Therapeutics...
BC Week In Review | Dec 8, 2017
Clinical News

Neuralstem reports additional Phase II data for NSI-189 in MDD

Neuralstem Inc. (NASDAQ:CUR) reported additional data from a Phase II trial of NSI-189 to treat major depressive disorder (MDD). In July, the company reported top-line data showing that both doses of NSI-189 missed the trial's...
BC Extra | Dec 6, 2017
Clinical News

Neuralstem rebounds on additional MDD data

Neuralstem Inc. (NASDAQ:CUR) gained $1.97 (176%) to $3.09 on Tuesday after reporting additional data from a Phase II trial of NSI-189 to treat major depressive disorder. In July, the company's stock fell 50% to $2.81...
BC Extra | Nov 9, 2017
Company News

Management tracks: Pfizer, Hansa

Pfizer Inc. (NYSE:PFE) hired Amrit Ray as global president of Pfizer essential health, R&D, effective Friday. He was SVP of external affairs at Johnson & Johnson (NYSE:JNJ). In his new role, Ray will be responsible...
BioCentury | Oct 6, 2017
Finance

High as a Kite

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...
BC Week In Review | Jul 28, 2017
Clinical News

Neuralstem's NSI-189 misses in Phase II for MDD

Neuralstem Inc. (NASDAQ:CUR) reported top-line data from a Phase II trial in 220 patients with major depressive disorder (MDD) showing that once- and twice-daily 40 mg doses of NSI-189 each missed the primary endpoint of...
BC Extra | Jul 25, 2017
Clinical News

Neuralstem sags after Phase II miss in MDD

Neuralstem Inc. (NASDAQ:CUR) fell $2.77 (50%) to $2.81 on Tuesday after it said lead compound NSI-189 missed the primary endpoint in a Phase II trial to treat major depressive disorder. Compared to placebo, NSI-189 failed...
BC Week In Review | Apr 13, 2017
Clinical News

Human neural stem cells: Ph I amended

Neuralstem amended an open-label, U.S. Phase I trial evaluating injectable NSI-566 to enroll an additional cohort of 4 patients with American Spinal Injury Association Impairment Scale level A (AIS-A) complete, quadriplegic, cervical injuries involving C5-C7...
Items per page:
1 - 10 of 123